BioNexus Gene Lab (BGLC) Receivables (2019 - 2026)

BioNexus Gene Lab (BGLC) has 8 years of Receivables data on file, last reported at $1.0 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables fell 37.56% year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.0 million (down 37.56% YoY), and the FY2025 full-year result was $1.3 million, down 38.44% from the prior year.
• Receivables rose to $1.0 million in Q1 2026, from $587613.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $2.9 million in Q2 2022 to a low of $587613.0 in Q4 2025.
• A 5-year average of $1.9 million and a median of $2.0 million in 2023 frame the typical range for Receivables.
• Peak annual rise in Receivables reached 76.24% in 2025, while the deepest fall reached 71.99% in 2025.
• Tracing BGLC's Receivables over 5 years: stood at $2.8 million in 2022, then fell by 29.35% to $2.0 million in 2023, then advanced by 7.26% to $2.1 million in 2024, then plunged by 71.99% to $587613.0 in 2025, then soared by 78.31% to $1.0 million in 2026.
• Business Quant data shows BGLC's Receivables at $1.0 million in Q1 2026, $587613.0 in Q4 2025, and $1.6 million in Q3 2025.